Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK, J&J Plan Filings For Third-To-Market IL-6 Inhibitor Sirukumab

This article was originally published in Scrip

Executive Summary

GlaxoSmithKline PLC and Janssen Biologics, a Johnson & Johnson subsidiary, will seek regulatory approvals for sirukumab in 2016 based on positive Phase III results in rheumatoid arthritis, setting the biologic up to compete with two other interleukin-6 (IL-6) inhibitors when it hits the market in 2017.

You may also be interested in...



Amgen Delivers Solid Q3 Sales, Little Insight On Key R&D Programs

Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.

Slow And Steady: Merck Advances COVID-19 Antiviral, Vaccine Programs

Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.

Amgen Faces Potential Lack Of Near-Commercial Assets

Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.

Topics

UsernamePublicRestriction

Register

LL1134468

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel